Publications

Cost-effectiveness of Haemophilus influenzae type b vaccine in Vietnam.

Le, P; GRIFFITHS, UK; Anh, DD; Franzini, L; Chan, W; Swint, JM;

2015

Vaccine, (2015).33 36 10.1016/j.vaccine.2015.05.050.

10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV) induces memory B cell responses in healthy Kenyan toddlers.

Muema, DM; Nduati, EW; Uyoga, M; Bashraheil, M; SCOTT, JA G; Hammitt, LL; Urban, BC;

2015

Clinical and experimental immunology, (2015).181 2 10.1111/cei.12637.

Individual-level factors associated with variation in mycobacterial-specific immune response: Gender and previous BCG vaccination status.

RHODES, SJ; KNIGHT, GM; FIELDING, K; Scriba, TJ; Pathan, AA; McShane, H; FLETCHER, H; WHITE, RG;

2015

Tuberculosis (Edinburgh, Scotland), (2015).96, 10.1016/j.tube.2015.10.002.

Thirty years of vaccination in Vietnam: Impact and cost-effectiveness of the national Expanded Programme on Immunization.

JIT, M; Dang, TT H; Friberg, I; Hoang, VM; Pham Huy, TK; Walker, N; Nguyen, VC; Tran, ND; Toda, K; Hutubessy, R; Fox, K; Nguyen, TH;

2015

Vaccine, (2015).33 Sup Suppl 10.1016/j.vaccine.2014.12.017.

Differential transcriptomic and metabolic profiles of M. africanum- and M. tuberculosis-infected patients after, but not before, drug treatment.

TIENTCHEU, LD; Maertzdorf, J; Weiner, J; ADETIFA, IM; Mollenkopf, H-J; SUTHERLAND, JS; Donkor, S; KAMPMANN, B; Kaufmann, SH E; DOCKRELL, HM; Ota, MO;

2015

Genes and immunity, (2015).16 5 10.1038/gene.2015.21.

Implementation of the malaria candidate vaccine RTS,S/AS01.

GREENWOOD, B; Doumbo, OK;

2015

Lancet, (2015).387 10016 10.1016/S0140-6736(15)00807-7.

Evidence-based decision-making for vaccine introductions: Overview of the ProVac International Working Group's experience.

Jauregui, B; Garcia, AG F; Bess Janusz, C; Blau, J; Munier, A; Atherly, D; Mvundura, M; Hajjeh, R; Lopman, B; CLARK, AD; BAXTER, L; Hutubessy, R; De Quadros, C; Andrus, JK;

2015

Vaccine, (2015).33 Sup 0 1 10.1016/j.vaccine.2014.10.090.

Consensus on the development of vaccines against naturally acquired melioidosis.

Limmathurotsakul, D; Funnell, SG P; Torres, AG; Morici, LA; Brett, PJ; Dunachie, S; Atkins, T; Altmann, DM; BANCROFT, G; PEACOCK, SJ; Steering Group on Melioidosis Vaccine Development,;

2015

Emerging infectious diseases, (2015).21 6 10.3201/eid2106.141480.

Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models.

Penny, MA; Verity, R; Bever, CA; Sauboin, C; Galactionova, K; FLASCHE, S; White, MT; Wenger, EA; Van de Velde, N; Pemberton-Ross, P; Griffin, JT; Smith, TA; Eckhoff, PA; Muhib, F; JIT, M; Ghani, AC;

2015

Lancet, (2015).387 10016 10.1016/S0140-6736(15)00725-4.

Estimated impact and cost-effectiveness of rotavirus vaccination in Senegal: A country-led analysis.

Diop, A; Atherly, D; Faye, A; Lamine Sall, F; CLARK, AD; Nadiel, L; Yade, B; Ndiaye, M; Fafa Cissé, M; Ba, M;

2015

Vaccine, (2015).33 Sup S1 10.1016/j.vaccine.2014.12.065.